Summary
The efficacy and tolerability of the dihydropyridine derivative nisoldipine was assessed in 36 patients with primary Raynaud's phenomenon.
Nisoldipine was given at doses of 5 mg and 10 mg daily for one month each in a placebo controlled double-blind cross-over trial. There was no subjective improvement in symptoms or changes in resting finger blood flow, platelet aggregability or red cell deformability after nisoldipine.
The incidence of unwanted effects was similar to that previously described with nifedipine, suggesting that plasma concentrations of nisoldipine were sufficient to cause pharmacodynamic effects.
Nisoldipine, in contrast to nifedipine is ineffective in the treatment of primary Raynaud's phenomen when given in a dose of up to 10 mg/day.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cardinal DC, Flower RJ (1980) The electronic aggregometer, a novel device for assessing platelet behaviour in blood. J Pharmacol Methods 3: 135–158
Corbin DO, Wood DA, MacIntyre CC, Housley E (1986) A randomised double-blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Eur Heart J 7: 165–170
Ekelund L-G (1978) Ca-blockers and peripheral circulation — physiological viewpoints. Acta Pharmacol Toxicol (Copenh) 43 [Suppl 1]: 33–43
Francis JL (1987) Improved assessment of impedance aggregometry using a microcomputer. Thromb Res 43: 851–855
Gjorup T, Hartling OJ, Kelbaek H, Nielsen SL (1986) Controlled double-blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. Eur J Clin Pharmacol 31: 387–389
Harkness J (1971) The viscosity of human blood plasma: Its measurement in health and disease. Biorheology 8: 171–193
Hills M, Armitage P (1979) The two-period cross-over clinical trial. Br J Clin Pharmacol 8: 7–20
Jeremy JY, Barradas M, Mikhailidis DP, Dandona P (1986) Effects of verapamil and nisoldipine on human platelets: In vivo and in vitro studies. Br J Clin Pharmacol 22: 201–202
Jones CR, Pasanisi F, Elliott HL, Reid JL (1985) Effects of verapamil and nisoldipine on human platelets: In vivo and in vitro studies. Br J Clin Pharmacol 20: 191–196
Kahan A, Amor B, Menkes CJ (1985) A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 44: 30–33
Kazda S, Garthoff B, Meyer H, Schlobmann K, Stoepel K, Towart R, Vater W, Wehinger E (1980) Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4 dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Ni-soldipine, Bayer K 5552). Arzneimittelforsch 30: 2144–2162
Kinney EL, Nicholas GG, Gallo J, Pontiero C, Zelis R (1982) The treatment of severe Raynaud's phenomenon with verapamil. J Clin Pharmacol 22: 74–76
Lucas GS, Simms MH, Caldwell NH, Alexander SJC, Stuart J (1984) Haemorrheological effects of prostaglandin E1 infusion in Raynaud's syndrome. J Clin Pathol 37: 870–873
Mani R, White JE (1985) The use of photoreflectance probes and transcutaneous oxygen electrodes for investigation of leg ulcers. Bioengineering and the skin 1: 207–217
Murer EH (1985) The role of platelet calcium. Semin Haematol 22: 313–323
Reid HL, Barnes AL, Lock PL, Dormandy JA, Dormandy TTL (1976) A simple method for measuring erythrocyte deformability. J Clin Pathol 29: 855–858
Rhedda A, McCans J, Willan AR, Ford PM (1985) A double-blind placebo controlled cross-over randomised trial of diltiazem in Raynaud's phenomenon. J Rheumatol 12: 724–727
Roath S (1986) Managing Raynaud's phenomenon. Br Med J 293: 88–89
Sarkozi J, Bookman AA, Mahon W, Ramsay C, Detsky AS, Keystonee EC (1986) Nifedipine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol 13: 331–336
Sowemimo-Coker SO, Debbas NMG, Kovacs IB, Turner P (1985) Ex vivo effects if nifedipine, nisoldipine and niterdipine on filterability of red blood cells from healthy volunteers. Br J Clin Pharmacol 20: 152–154
Vayssairat M, Capron L, Fiessinger J-N, Mathieu J-F, Mousset E (1981) Calcium channel blockers and Raynaud's disease. Ann Intern Med 95: 243
Waller DG, Challenor VF, Francis DA, Roath OS (1986) Clinical and rheological effects of nifedipine in Raynaud's phenomenon. Br J Clin Pharmacol 22: 449–454
Weed RI, Le Celle PW, Merrill EW (1969) Metabolic dependance of red cell deformability. J Clin Invest 48: 795–809
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Challenor, V.F., Waller, D.G., Francis, D.A. et al. Nisoldipine in primary Raynaud's phenomenon. Eur J Clin Pharmacol 33, 27–30 (1987). https://doi.org/10.1007/BF00610375
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00610375